Allergan plc announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.
Note that Natrelle Inspira is the only line of breast implants with three levels of cohesive gel products available in the U.S. The brand boasts varying gel firmness for different levels of form stability.
With the FDA approval for Natrelle SoftTouch, Allergan’s plastic surgery portfolio will now have the broadest variety of implants among its peers and the company will now be able to provide surgeons with a wider array of options.
Allergan’s three-month share price movement shows that the stock has marginally outperformed the Zacks classified Medical-Generic Drugs industry. Specifically, the company lost 11%, while the industry lost 12.4%.
We remind investors that in Sep 2016, Allergan received FDA approval for marketing the Natrelle Inspira Cohesive line of breast implants for breast reconstruction, augmentation or revision surgery.
These implants, which offer a high gel fill ratio and utilize the company’s highly cohesive gel, are available in two versions – smooth and textured.
Zacks Rank & Key Picks
Allergan currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Arena Pharmaceuticals, Inc. , Cambrex Corporation and Kamada Ltd. . While Cambrex sport a Zacks Rank #1 (Strong Buy), Arena Pharma and Kamada carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Arena’s earnings estimates declined from 36 cents to 34 cents for 2016 and from 33 cents to 32 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 11.43%.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.6% in the past one month.
Kamada’s loss estimates widened from 6 cents to 10 cents for 2016 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 31.25%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Image: Bigstock
Allergan Natrelle Inspira Breast Implants Approved in the U.S.
Allergan plc announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.
Note that Natrelle Inspira is the only line of breast implants with three levels of cohesive gel products available in the U.S. The brand boasts varying gel firmness for different levels of form stability.
With the FDA approval for Natrelle SoftTouch, Allergan’s plastic surgery portfolio will now have the broadest variety of implants among its peers and the company will now be able to provide surgeons with a wider array of options.
Allergan’s three-month share price movement shows that the stock has marginally outperformed the Zacks classified Medical-Generic Drugs industry. Specifically, the company lost 11%, while the industry lost 12.4%.
We remind investors that in Sep 2016, Allergan received FDA approval for marketing the Natrelle Inspira Cohesive line of breast implants for breast reconstruction, augmentation or revision surgery.
These implants, which offer a high gel fill ratio and utilize the company’s highly cohesive gel, are available in two versions – smooth and textured.
ALLERGAN PLC Price
ALLERGAN PLC Price | ALLERGAN PLC Quote
Zacks Rank & Key Picks
Allergan currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Arena Pharmaceuticals, Inc. , Cambrex Corporation and Kamada Ltd. . While Cambrex sport a Zacks Rank #1 (Strong Buy), Arena Pharma and Kamada carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Arena’s earnings estimates declined from 36 cents to 34 cents for 2016 and from 33 cents to 32 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 11.43%.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.6% in the past one month.
Kamada’s loss estimates widened from 6 cents to 10 cents for 2016 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 31.25%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>